Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD
Aldosterone synthase inhibition may affect cortisol synthesis due to homology between CYP11B2 (aldosterone synthase) and CYP11B1. The selectivity of vicadrostat, a highly selective aldosterone synthase inhibitor, for aldosterone suppression was evaluated by corticosteroid assessment in participants...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 2026
|
| In: |
European journal of endocrinology
Year: 2026, Jahrgang: 194, Heft: 1, Pages: 46-57 |
| ISSN: | 1479-683X |
| DOI: | 10.1093/ejendo/lvaf265 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1093/ejendo/lvaf265
|
| Verfasserangaben: | Isabella A. Gashaw, Katherine R. Tuttle, Manuel Monroy Kuhn, Sina Pleiner, Denis Delic, Lisa Cronin, Shimoli V. Shah, and Peter Rossing |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1962187756 | ||
| 003 | DE-627 | ||
| 005 | 20260223095436.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260223s2026 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ejendo/lvaf265 |2 doi | |
| 035 | |a (DE-627)1962187756 | ||
| 035 | |a (DE-599)KXP1962187756 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gashaw, Isabella |d 1972- |e VerfasserIn |0 (DE-588)128568143 |0 (DE-627)376203439 |0 (DE-576)297218425 |4 aut | |
| 245 | 1 | 0 | |a Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD |c Isabella A. Gashaw, Katherine R. Tuttle, Manuel Monroy Kuhn, Sina Pleiner, Denis Delic, Lisa Cronin, Shimoli V. Shah, and Peter Rossing |
| 264 | 1 | |c January 2026 | |
| 300 | |b Diagramme | ||
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 23. Deczmber 2025 | ||
| 500 | |a Gesehen am 23.02.2026 | ||
| 520 | |a Aldosterone synthase inhibition may affect cortisol synthesis due to homology between CYP11B2 (aldosterone synthase) and CYP11B1. The selectivity of vicadrostat, a highly selective aldosterone synthase inhibitor, for aldosterone suppression was evaluated by corticosteroid assessment in participants with albuminuric CKD (with or without T2D) in a randomized, double-blind, placebo-controlled phase 2 trial (NCT05182840)After randomization to receive empagliflozin 10 mg once-daily or matched placebo for an 8-week run-in (plus renin-angiotensin system inhibitors), 586 participants were re-randomized to receive vicadrostat (3, 10, or 20 mg once-daily) or matched placebo for 14 weeks, with a 4-week follow-up. Our analysis included 410 participants who completed treatment. Plasma corticosteroids (aldosterone, cortisol, corticosterone, 11-deoxycorticosterone, and 11-deoxycortisol) were measured using liquid chromatography tandem mass spectrometry. Effects were evaluated via mixed effects models for repeated measures.Dose-dependent suppression of plasma aldosterone was observed, with maximum suppression at week 14 resulting in geometric mean changes of −49.5% (95% CI: −68.7, −18.5) and −52.1% (−70.7, −21.6) for vicadrostat 20 mg given with and without empagliflozin, respectively. From baseline to week 14, increases were observed in mean plasma corticosterone, 11-deoxycorticosterone, and 11-deoxycortisol. Plasma 11-deoxycorticosterone increased by 222.8% (95% CI: 103.2, 412.7) and 231.5% (95% CI: 106.4, 432.2) for vicadrostat 20 mg given with or without empagliflozin, respectively, and plasma 11-deoxycortisol increased by 112.5% (95% CI: 36.0, 231.9) and 121.0% (95% CI: 40.0, 249.0) for the same dose groups. No increase or decrease in plasma cortisol was observed across vicadrostat dose groups with or without empagliflozin. Aldosterone suppression was sustained to 4 weeks post-treatment, while precursor levels normalized within 1 week of treatment cessation.Vicadrostat, with or without background empagliflozin, selectively suppressed aldosterone over cortisol. These findings will be explored in a phase 3 trial program. | ||
| 700 | 1 | |a Tuttle, Katherine R |e VerfasserIn |4 aut | |
| 700 | 1 | |a Monroy Kuhn, Manuel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pleiner, Sina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Delic, Denis |e VerfasserIn |0 (DE-588)1388217015 |0 (DE-627)1950440931 |4 aut | |
| 700 | 1 | |a Cronin, Lisa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shah, Shimoli V |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rossing, Peter |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of endocrinology |d Oxford : Oxford University Press, 1994 |g 194(2026), 1 vom: Jan., Seite 46-57 |h Online-Ressource |w (DE-627)30151741X |w (DE-600)1485160-X |w (DE-576)079421466 |x 1479-683X |7 nnas |a Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD |
| 773 | 1 | 8 | |g volume:194 |g year:2026 |g number:1 |g month:01 |g pages:46-57 |g extent:12 |a Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD |
| 856 | 4 | 0 | |u https://doi.org/10.1093/ejendo/lvaf265 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260223 | ||
| 993 | |a Article | ||
| 994 | |a 2026 | ||
| 998 | |g 1388217015 |a Delic, Denis |m 1388217015:Delic, Denis |d 60000 |e 60000PD1388217015 |k 0/60000/ |p 5 | ||
| 999 | |a KXP-PPN1962187756 |e 4921348138 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1962187756","language":["eng"],"physDesc":[{"noteIll":"Diagramme","extent":"12 S."}],"name":{"displayForm":["Isabella A. Gashaw, Katherine R. Tuttle, Manuel Monroy Kuhn, Sina Pleiner, Denis Delic, Lisa Cronin, Shimoli V. Shah, and Peter Rossing"]},"id":{"doi":["10.1093/ejendo/lvaf265"],"eki":["1962187756"]},"origin":[{"dateIssuedKey":"2026","dateIssuedDisp":"January 2026"}],"person":[{"given":"Isabella","family":"Gashaw","role":"aut","display":"Gashaw, Isabella"},{"given":"Katherine R","family":"Tuttle","role":"aut","display":"Tuttle, Katherine R"},{"family":"Monroy Kuhn","display":"Monroy Kuhn, Manuel","role":"aut","given":"Manuel"},{"given":"Sina","display":"Pleiner, Sina","role":"aut","family":"Pleiner"},{"given":"Denis","family":"Delic","display":"Delic, Denis","role":"aut"},{"given":"Lisa","family":"Cronin","role":"aut","display":"Cronin, Lisa"},{"role":"aut","display":"Shah, Shimoli V","family":"Shah","given":"Shimoli V"},{"family":"Rossing","role":"aut","display":"Rossing, Peter","given":"Peter"}],"title":[{"title":"Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD","title_sort":"Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD"}],"relHost":[{"origin":[{"dateIssuedKey":"1994","publisher":"Oxford University Press ; BioScientifica Ltd.","publisherPlace":"Oxford ; Bristol","dateIssuedDisp":"1994-"}],"title":[{"subtitle":"EJE : clinical and translational endocrinology from around the globe","title":"European journal of endocrinology","title_sort":"European journal of endocrinology"}],"disp":"Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKDEuropean journal of endocrinology","part":{"volume":"194","pages":"46-57","text":"194(2026), 1 vom: Jan., Seite 46-57","year":"2026","extent":"12","issue":"1"},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"recId":"30151741X","id":{"zdb":["1485160-X"],"issn":["1479-683X"],"eki":["30151741X"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["Volume 130, issue 1 (Jan 1994)-"],"note":["Gesehen am 21.08.25"],"titleAlt":[{"title":"EJE"},{"title":"European journal of endocrinology"},{"title":"official journal of the European Federation of Endocrine Societies"},{"title":"EJE"}]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Online veröffentlicht: 23. Deczmber 2025","Gesehen am 23.02.2026"]} | ||
| SRT | |a GASHAWISABPHARMACODY2026 | ||